BiOptix LLC, a Boulder-based company founded off biosensory technology developed by Nobel Prize-winner John “Jan” Hall, recently landed more than $6 million in investment capital, Securities and Exchange Commission filings show.
The company raised $6.2 million as part of an $8 million offering, according to the SEC filings. Twenty-five investors partook in the round.
The investment has not been publicly announced. BiOptix officials weren’t immediately available for comment.
The new capital comes roughly three months after BiOptix announced its 404pi product, a surface plasmon resonance instrument that was designed to measure interactions between proteins and also between proteins and small molecules.
BiOptix’s range of Enhanced SPR technologies monitor biological interactions and can be used in applications such as disease detection.
To-date, BiOptix has raised about $8 million, which includes a $3 million Series A round in 2009 and a $250,000 Small Business Innovative Research award from the National Institutes of Health and the National Cancer Institute in 2010. In 2011, the company disclosed offerings totaling nearly $5 million, according to SEC filings.
